TIBET PHARMA(SH:600211) Zheng Quan Zhi Xing·2025-07-16 09:07Summary of Key Points Core Viewpoint - The company has provided guarantees for its subsidiaries, which are essential for their operational financing and growth, while ensuring that these guarantees are within the approved limits and backed by counter-guarantees from the subsidiaries [1][2][3]. Group 1: Guarantee Overview - The company has provided a guarantee of RMB 107.80 million for its wholly-owned subsidiary, Tibet Nordicon Biopharmaceutical Sales Co., Ltd., and RMB 100 million for its controlling subsidiary, Tibet Nordicon Pharmaceutical Co., Ltd. [1][2] - The total actual guarantee balance provided by the company is RMB 218.80 million for the biopharmaceutical subsidiary and RMB 350 million for the pharmaceutical subsidiary as of the announcement date [1][2]. - Both subsidiaries have provided counter-guarantees to the company [1][2]. Group 2: Internal Decision-Making Process - The company held board meetings on March 13, 2025, and April 8, 2025, to approve the guarantee and credit limit proposals, allowing a total credit limit of up to RMB 1 billion for the year 2025 [2][3]. - The controlling subsidiary's credit limit is capped at RMB 800 million, with the company providing joint liability guarantees for all debts incurred within this limit [2][3]. Group 3: Financial Data of Subsidiaries - Tibet Nordicon Biopharmaceutical Sales Co., Ltd. has total assets of RMB 440.84 million, net assets of RMB 130.46 million, total liabilities of RMB 310.38 million, operating income of RMB 1.29 billion, and a net profit of RMB 67.12 million, with an asset-liability ratio of 70.41% [4]. - Tibet Nordicon Pharmaceutical Co., Ltd. has total assets of RMB 1.13 billion, net assets of RMB 672.72 million, total liabilities of RMB 452.93 million, operating income of RMB 1.37 billion, and a net profit of RMB 121.28 million, with an asset-liability ratio of 40.24% [5]. Group 4: Guarantee Agreement Details - The guarantee for Tibet Nordicon Biopharmaceutical Sales Co., Ltd. is with China Bank, with a limit of RMB 107.80 million, covering all principal, interest, penalties, and related costs for three years [5][6]. - The guarantee for Tibet Nordicon Pharmaceutical Co., Ltd. is with Citic Bank, with a limit of RMB 100 million, covering similar financial obligations for three years [5][6]. Group 5: Risk Management and Control - The company maintains effective control over the operational risks and decision-making of its subsidiaries, ensuring that the risks associated with the guarantees are manageable [6][7]. - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 800 million, with no overdue guarantees reported [7].